Our study concluded that the racemic trans-(±)-kusunokinin may have inhibited breast cancer cells primarily through the binding and suppression of CSF1R by trans-(−)-kusunokinin, in addition to the binding of trans-(−) or trans-(+) isomers to other target proteins. This evidence concerns the gene CSF1R and breast cancer.